Skip Main Navigation
Page Content
This event has ended

Save This Event

Event Saved

Conference on Cell & Gene Therapy for HIV Cure 2016

defeatHIV

Thursday, August 4, 2016 at 8:00 AM - Friday, August 5, 2016 at 2:00 PM (PDT)

Conference on Cell & Gene Therapy for HIV Cure 2016

Registration Information

Registration Type Sales End Price Fee
Quantity
Early Bird Registration (ends June 25) Ended $450.00 $0.00
Regular Rate (June 26-August 4) Ended $550.00 $0.00
TRAINEES/Post Docs and Grad Students (Invited) Ended Free $0.00
Space Needle Dinner Plus One Ended $60.00 $0.00

Event Details

Keynote Speaker: Lawrence Corey, MD, President and Director Emeritus of Fred Hutchinson Cancer Research Center (FHCRC), professor of Medicine and Laboratory Medicine at the University of Washington. Dr. Corey is also Principal Investigator of the HIV Vaccine Trials Network, an international collaboration of scientists and institutions dedicated to accelerating the development of HIV vaccines.

This meeting is designed to foster scientific collegiality and to continue to build the important scientific collaborations and community relationships that are critical to solving one of the greatest puzzles of global health in human history.

For conference updates: http://cgt4hivcure2016.org

Have questions about Conference on Cell & Gene Therapy for HIV Cure 2016? Contact defeatHIV

When & Where


Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N.
Seattle, WA 98109

Thursday, August 4, 2016 at 8:00 AM - Friday, August 5, 2016 at 2:00 PM (PDT)


  Add to my calendar

Organizer

defeatHIV

defeatHIV, the Delaney Cell and Genome Engineering Initiative, is a consortium of committed investigators found in both academic and private sector research institutions, working together for a common purpose—to eradicate HIV.  As a Martin Delaney Collaboratory (MDC) program, we are inspired to re-examine existing approaches in the fight against AIDS and to focus our energies on developing innovative and novel strategies to abrogate the spread of this debilitating disease. Our core technologies utilize the latest cell and gene therapy approaches to eliminate latently-infected cells after viral reactivation, and improve the body’s ability to control unpredictable reactivation events from a therapeutically-reduced reservoir.  It is our mission to leverage the knowledge, expertise and resources of the consortium to generate a realistic and promising pathway toward the ultimate goal of an HIV cure.

  Contact the Organizer

Please log in or sign up

In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.